SG11201702606TA - Antibodies that bind ebola glycoprotein and uses thereof - Google Patents
Antibodies that bind ebola glycoprotein and uses thereofInfo
- Publication number
- SG11201702606TA SG11201702606TA SG11201702606TA SG11201702606TA SG11201702606TA SG 11201702606T A SG11201702606T A SG 11201702606TA SG 11201702606T A SG11201702606T A SG 11201702606TA SG 11201702606T A SG11201702606T A SG 11201702606TA SG 11201702606T A SG11201702606T A SG 11201702606TA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- ebola glycoprotein
- bind ebola
- bind
- glycoprotein
- Prior art date
Links
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 title 1
- 102000003886 Glycoproteins Human genes 0.000 title 1
- 108090000288 Glycoproteins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462059746P | 2014-10-03 | 2014-10-03 | |
PCT/US2015/053871 WO2016054598A2 (fr) | 2014-10-03 | 2015-10-02 | Anticorps qui se lient à la glycoprotéine du virus ébola et utilisations associés |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201702606TA true SG11201702606TA (en) | 2017-04-27 |
Family
ID=54291751
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201902924RA SG10201902924RA (en) | 2014-10-03 | 2015-10-02 | Antibodies that bind ebola glycoprotein and uses thereof |
SG11201702606TA SG11201702606TA (en) | 2014-10-03 | 2015-10-02 | Antibodies that bind ebola glycoprotein and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201902924RA SG10201902924RA (en) | 2014-10-03 | 2015-10-02 | Antibodies that bind ebola glycoprotein and uses thereof |
Country Status (8)
Country | Link |
---|---|
US (2) | US10894818B2 (fr) |
EP (1) | EP3201226A2 (fr) |
JP (2) | JP2017531642A (fr) |
CN (1) | CN106999566B (fr) |
AU (2) | AU2015327819B2 (fr) |
CA (1) | CA2963470A1 (fr) |
SG (2) | SG10201902924RA (fr) |
WO (1) | WO2016054598A2 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
EA201792500A1 (ru) | 2015-05-13 | 2018-04-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Aav-опосредованная экспрессия антител против гриппа и способы их использования |
EP3302563A1 (fr) * | 2015-05-29 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Anticorps contre la glycoprotéine du virus ebola humanisés et procédés d'utilisation |
LT3322701T (lt) | 2015-07-15 | 2019-07-10 | F. Hoffmann-La Roche Ag | Etinilo dariniai kaip metabotropinių glutamato receptorių moduliatoriai |
US20190240328A1 (en) * | 2016-09-24 | 2019-08-08 | The Trustees Of The University Of Pennsylvania | Novel humanized anti-ebola antibodies useful in preventing ebola infections |
AU2018221172A1 (en) | 2017-02-17 | 2019-09-05 | Adimab, Llc | Monoclonal antibodies and cocktails for treatment of Ebola infections |
SG10201913833PA (en) | 2017-02-28 | 2020-03-30 | Univ Pennsylvania | Influenza vaccines based on aav vectors |
SG10201912976WA (en) | 2017-02-28 | 2020-02-27 | Univ Pennsylvania | Adeno-associated virus (aav) clade f vector and uses therefor |
JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
CN113512111B (zh) * | 2017-03-10 | 2023-08-15 | 北京天广实生物技术股份有限公司 | 抗埃博拉病毒单克隆抗体、其制备方法及用途 |
CN106868025B (zh) * | 2017-03-13 | 2020-01-21 | 中国人民解放军军事医学科学院生物工程研究所 | 用酵母制备三聚体埃博拉病毒糖蛋白突变体的方法 |
US20200216519A1 (en) * | 2017-09-15 | 2020-07-09 | The Wistar Institute Of Anatomy And Biology | Dna antibody constructs for use against ebola virus |
CN108299559B (zh) * | 2017-12-29 | 2021-11-26 | 上海科技大学 | Zaire型埃博拉病毒检测抗体及其制备方法及应用 |
TW202016125A (zh) * | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
EP3921413A1 (fr) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Lignée cellulaire humanisée |
US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
JP2023537002A (ja) * | 2020-08-06 | 2023-08-30 | アブプロ コーポレーション | 抗クローディン18.2多重特異性抗体及びそれらの使用 |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
EP0154316B1 (fr) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Lymphokine chimiquement modifiée et son procédé de préparation |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
EP0832981A1 (fr) | 1987-02-17 | 1998-04-01 | Pharming B.V. | Séquences d'ADN pour diriger des protéines vers les glandes mammaires, afin d'être secrétées efficacement |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0546073B1 (fr) | 1990-08-29 | 1997-09-10 | GenPharm International, Inc. | production et utilisation des animaux non humains transgeniques capable de produire des anticorps heterologues |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
WO1992022645A1 (fr) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Animaux transgeniques non humains presentant une deficience immunitaire |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
CA2113113A1 (fr) | 1991-07-08 | 1993-01-21 | Simon W. Kantor | Copolymere sequence a cristaux liquides thermotropiques |
DE69233782D1 (de) | 1991-12-02 | 2010-05-20 | Medical Res Council | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
WO1999054342A1 (fr) | 1998-04-20 | 1999-10-28 | Pablo Umana | Modification par glycosylation d'anticorps aux fins d'amelioration de la cytotoxicite cellulaire dependant des anticorps |
ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
AU7089600A (en) | 1999-08-30 | 2001-03-26 | U.S. Army Medical Research Institute Of Infectious Diseases | Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein |
CA2430013C (fr) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Rongeurs transgeniques et transchromosomiques pour la fabrication d'anticorps humains |
CN100423777C (zh) | 2001-10-25 | 2008-10-08 | 杰南技术公司 | 糖蛋白组合物 |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
CN1930288B (zh) | 2002-04-09 | 2012-08-08 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
WO2005044853A2 (fr) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anticorps anti-vegf |
NZ556788A (en) * | 2005-01-05 | 2011-03-31 | Biogen Idec Inc | Humanized CRIPTO binding molecules with CDRs from murine B3F6 |
NZ560414A (en) | 2005-02-18 | 2011-04-29 | Medarex Inc | Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues |
AU2006262231B2 (en) * | 2005-06-20 | 2013-01-24 | Psma Development Company, Llc | PSMA antibody-drug conjugates |
DE102007036200A1 (de) | 2007-08-02 | 2009-02-05 | Knorr-Bremse Systeme für Nutzfahrzeuge GmbH | Induktiver Weg- oder Drehwinkelsensor mit zwischen zwei Spulen angeordnetem Abschirmblech |
US8513391B2 (en) | 2008-02-01 | 2013-08-20 | Steven Jones | Monoclonal antibodies for Ebola and Marburg viruses |
RU2593720C2 (ru) | 2008-12-19 | 2016-08-10 | Макродженикс, Инк. | Ковалентные диантитела и их применение |
WO2011071574A2 (fr) | 2009-09-02 | 2011-06-16 | United States Deparment Of The Army, As Represented By The Secretary Of The Army | Anticorps monoclonaux dirigés contre la glycoprotéine du virus ebola souche soudan boniface |
SI2509409T1 (sl) | 2009-12-10 | 2016-12-30 | Regeneron Pharmaceuticals, Inc. | Miši, ki tvorijo protitelesa težke verige |
ES2547142T5 (es) | 2010-02-08 | 2021-12-09 | Regeneron Pharma | Cadena ligera común de ratón |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
PT3034608T (pt) | 2010-06-22 | 2019-05-28 | Regeneron Pharma | Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana |
GB2541596A (en) * | 2014-06-03 | 2017-02-22 | Us Gov Sec Army | Method and composition for determining specific antibody responses to species of filovirus |
-
2015
- 2015-10-02 SG SG10201902924RA patent/SG10201902924RA/en unknown
- 2015-10-02 AU AU2015327819A patent/AU2015327819B2/en not_active Ceased
- 2015-10-02 WO PCT/US2015/053871 patent/WO2016054598A2/fr active Application Filing
- 2015-10-02 CA CA2963470A patent/CA2963470A1/fr not_active Abandoned
- 2015-10-02 CN CN201580064291.3A patent/CN106999566B/zh not_active Expired - Fee Related
- 2015-10-02 JP JP2017517793A patent/JP2017531642A/ja active Pending
- 2015-10-02 SG SG11201702606TA patent/SG11201702606TA/en unknown
- 2015-10-02 EP EP15778588.2A patent/EP3201226A2/fr not_active Withdrawn
- 2015-10-02 US US15/515,746 patent/US10894818B2/en active Active
-
2020
- 2020-10-05 JP JP2020168479A patent/JP2021001226A/ja active Pending
- 2020-12-04 US US17/112,581 patent/US20210095007A1/en not_active Abandoned
-
2021
- 2021-05-17 AU AU2021203156A patent/AU2021203156A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2021001226A (ja) | 2021-01-07 |
CA2963470A1 (fr) | 2016-04-07 |
WO2016054598A2 (fr) | 2016-04-07 |
AU2015327819B2 (en) | 2021-07-01 |
AU2015327819A1 (en) | 2017-04-27 |
US10894818B2 (en) | 2021-01-19 |
WO2016054598A3 (fr) | 2016-05-19 |
JP2017531642A (ja) | 2017-10-26 |
EP3201226A2 (fr) | 2017-08-09 |
SG10201902924RA (en) | 2019-05-30 |
CN106999566A (zh) | 2017-08-01 |
AU2021203156A1 (en) | 2021-06-10 |
US20210095007A1 (en) | 2021-04-01 |
CN106999566B (zh) | 2022-01-28 |
US20170298120A1 (en) | 2017-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1254861A1 (zh) | 抗lag3抗體及其用途 | |
HK1255067A1 (zh) | 抗c10orf54抗體及其用途 | |
HK1243440A1 (zh) | 抗白細胞介素-33抗體及其用途 | |
SG11201702606TA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
HK1252615A1 (zh) | Il-8-結合抗體及其應用 | |
HK1249911A1 (zh) | 抗muc16抗體及其應用 | |
HK1250238A1 (zh) | 抗angptl8抗體及其用途 | |
ZA201605894B (en) | Anti-egfrviii antibodies and uses thereof | |
HK1256381A1 (zh) | 抗pacap抗體及其用途 | |
IL247277A0 (en) | Monoclonal antibodies against Ebola | |
ZA201701663B (en) | Anti-il-25 antibodies and uses thereof | |
GB201503387D0 (en) | Anti-carbapenem antibodies and uses thereof | |
IL247590A0 (en) | Bispecific antibodies and their uses | |
HK1254240A1 (zh) | 抗羥腐胺賴氨酸抗體及其用途 |